RayzeBio is a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets.
RayzeBio aims to improve clinical benefit by efficiently developing innovative tumor-targeted small molecule medicines that harness the power of radioisotopes.
RayzeBio was co-founded in 2020 by Deborah Charych, Aaron Kantoff and Aron Knickerbocker. The company is headquartered in San Diego, California.
RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company's lead clinical asset, RYZ101, is poised to be the first Actinium-225 (Ac225) approved drug.
RayzeBio is completing more than 200 in vivo studies, thus gaining key proprietary insights to discover novel drug candidates capable of delivering therapeutic radioisotopes to tumor associated antigens.
RayzeBio is establishing and entering into a licensing agreement with Ablaze Pharmaceuticals, a biotechnology company that is focused on development and commercialization of radiopharmaceuticals for China.
RayzeBio is backed by Venrock Healthcare Capital Partners, Viking Global Investors, OrbiMed, Versant Ventures, Wellington Management, venBio Partners, Perceptive Advisors, Sofinnova Investments, Vivo Capital, Redmile Group, Ally Bridge Group, Sands Capital, and others. The company raised $160M in Series D round on Sep 13, 2022. This brings RayzeBio's total funding to $418M to date.